Discover the power of real-time signals plus AI
Every funding round, exec hire, M&A move, contract, and sentiment shift on Loyal — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
Loyal Raises $100M Series C, Led by age1, to Advance the First Canine Longevity Drug.
Amount Raised
$100 Million
Round Type
series c
Investors
Description
Loyal, a clinical-stage animal health company, has raised $100M in Series C funding led by age1. The funding will support the development of an FDA-approved drug for canine lifespan extension. With this round, Loyal has received over $250M since its founding. The capital will help Loyal meet remaining FDA requirements to bring their lead program to market.
Related People
Sign in to view contact details
Sign in to view contact details
Funding Insights
Based on industry dataWatching Loyal? See every signal — funding, hires, M&A, contracts, sentiment.
See plans